Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Α. Dimopoulos, Meletios; Dytfeld, Dominik; Grosicki, Sebastian; Moreau, Philippe; Takezako, Naoki; Hori, Mitsuo; Leleu, Xavier; LeBlanc, Richard; Suzuki, Kenshi; S. Raab, Marc; G. Richardson, Paul; Popa McKiver, Mihaela; Jou, Ying-Ming; G. Shelat, Suresh; Robbins, Michael; T. Rafferty, Brian; F. San Miguel, Jesús

doi:10.1056/nejmoa1805762

Public

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Published in New England Journal of Medicine • Nov 7, 2018

Authors:

Meletios Α. Dimopoulos

Dominik Dytfeld

Sebastian Grosicki

Abstract

BACKGROUND: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with mul...

Subject

Pomalidomide

Lenalidomide

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!